RSV vaccine study for healthy adults aged 18 to 79
Part of Infections, Lungs & breathing clinical trials.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult between 18 and 79 years old.
- You have a body weight of at least 110 lbs (men) or 99 lbs (women) and a body mass index (BMI) between 18.5 and 35.
- If you are a woman who could become pregnant, you must not be pregnant or breastfeeding, and you must use effective birth control from 30 days before the vaccine until 6 months after.
- If you are a sexually active man who is not sterilized, you must use effective birth control from 30 days before the vaccine until 6 months after.
- You have not had any prior RSV vaccine (licensed or experimental).
- You do not have certain heart problems, uncontrolled high blood pressure, a bleeding disorder, a weakened immune system, or a history of severe allergic reactions to vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
This study tests a new RSV vaccine to see if it is safe for healthy adults. It uses mRNA technology to help your body build protection against RSV, a common respiratory virus.
Hear when a new Respiratory Syncytial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.